Page last updated: 2024-11-13
kibdelomycin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
kibdelomycin: an antibiotic that inhibits both gyrase and DNA topoisomerase IV; isolated from Kibdelosporangium; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 71463014 |
CHEMBL ID | 2205318 |
MeSH ID | M000610479 |
Synonyms (3)
Synonym |
---|
CHEMBL2205318 |
kibdelomycin |
bdbm50406470 |
Research Excerpts
Overview
Kibdelomycin is a recently discovered natural-product antibiotic. It inhibits bacterial growth by inhibiting the bacterial DNA replication enzymes DNA gyrase and topoisomerase IV.
Excerpt | Reference | Relevance |
---|---|---|
"Kibdelomycin A is a potent inhibitor of DNA gyrase and topoisomerase IV, inhibits DNA synthesis and shows whole cell antibiotic activity, albeit, less potently than kibdelomycin." | ( Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. Allocco, J; de la Cruz, M; Donald, RG; Dorso, K; Genilloud, O; Goetz, MA; Martín, J; Onishi, R; Phillips, JW; Polishook, J; Salowe, S; Sigmund, J; Singh, SB; Smith, SK; Vicente, F; Wiltsie, J; Zink, DL, 2012) | 2.54 |
"Kibdelomycin is a recently discovered natural-product antibiotic that inhibits bacterial growth by inhibiting the bacterial DNA replication enzymes DNA gyrase and topoisomerase IV." | ( Kibdelomycin is a bactericidal broad-spectrum aerobic antibacterial agent. Balibar, CJ; Dayananth, P; Fukuda, Y; Garlisi, CG; Ha, S; Kishii, R; Lu, J; Singh, SB; Takei, M; Young, K, 2015) | 2.58 |
"Kibdelomycin is a complex novel antibiotic, discovered by applying a highly sophisticated chemical-genetic Staphylococcus aureus Fitness Test (SaFT) approach, that inhibits the clinically established bacterial targets, gyrase and topoisomerase IV. " | ( Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type II topoisomerase. Singh, SB, 2016) | 2.17 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
"56mg/kg by oral dosing without systemic exposure." | ( Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type II topoisomerase. Singh, SB, 2016) | 0.73 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
DNA gyrase subunit B | Staphylococcus aureus | IC50 (µMol) | 0.0090 | 0.0040 | 1.5020 | 7.7000 | AID1359519; AID717074 |
DNA gyrase subunit A | Staphylococcus aureus | IC50 (µMol) | 0.0090 | 0.0040 | 1.9839 | 7.7000 | AID717074 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Bioassays (26)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID717075 | Inhibition of Escherichia coli topoisomerase-4 | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717082 | Antibacterial activity against Enterococcus faecalis CL8516 | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID1064473 | Antibacterial activity against Escherichia coli MB5746 harboring envA1/TolC efflux pump mutant assessed as growth inhibition after 20 hrs by agar dilution method | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | New natural products as new leads for antibacterial drug discovery. |
AID717071 | Inhibition of Escherichia coli ATPase activity of topoisomerase-4 | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717072 | Inhibition of Escherichia coli ATPase activity of DNA gyrase | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717085 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus MB 2865 in presence of 50% human serum | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717073 | Inhibition of Staphylococcus aureus topoisomerase-4 | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID1064474 | Antibacterial activity against Escherichia coli MB2884 assessed as growth inhibition after 20 hrs by agar dilution method | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | New natural products as new leads for antibacterial drug discovery. |
AID717076 | Inhibition of Escherichia coli DNA gyrase | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717080 | Antibacterial activity against Haemophilus influenzae MB4572 | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717070 | Antibacterial activity against wild type Staphylococcus aureus MB 5957 | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717081 | Antibacterial activity against Bacillus subtilis MB964 | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717084 | Antibacterial activity against methicillin-resistant Staphylococcus aureus COL MB 5393 | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717083 | Antibacterial activity against Streptococcus pneumoniae CL2883 in presence of 2.5% lysed horse blood | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717067 | Antibacterial activity against ciprofloxacin-resistant Staphylococcus aureus MB 5785 (R34) | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717068 | Antibacterial activity against coumermycin A1-resistant Staphylococcus aureus MB 5957/H7 harboring GyrB Gln136Glu, Ile175Thr, Leu455Ile mutant | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717074 | Inhibition of Staphylococcus aureus DNA gyrase | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717086 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus MB 2865 | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717077 | Antifungal activity against Candida albicans MY1055 | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID1064475 | Antibacterial activity against methicillin resistant Staphylococcus aureus COL MB5393 assessed as growth inhibition after 20 hrs by agar dilution method | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | New natural products as new leads for antibacterial drug discovery. |
AID717069 | Antibacterial activity against novobiocin-resistant Staphylococcus aureus MB 5957/A8 harboring GyrB ASP89Gly mutant | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717078 | Antibacterial activity against Escherichia coli MB5746 expressing envA1, tolC | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID717066 | Antibacterial activity against ciprofloxacin-resistant Staphylococcus aureus MB 5786 (R35) | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID1359519 | Inhibition of Staphylococcus aureus GyrB | 2018 | European journal of medicinal chemistry, May-25, Volume: 152 | New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV. |
AID717079 | Antibacterial activity against Escherichia coli MB2884 | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. |
AID1064476 | Antibacterial activity against methicillin sensitive Staphylococcus aureus MB2865 assessed as growth inhibition after 20 hrs by agar dilution method | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | New natural products as new leads for antibacterial drug discovery. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 8 (80.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 22.78
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.78) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (30.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (70.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |